Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Clinical trial NCT05113355 · UNKNOWN

Trial details

NCT number: NCT05113355
Sponsor: Peking Union Medical College Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Tumors Neuroendocrine Tumor Grade 3 Neuroendocrine Carcinoma Neuroendocrine Neoplasm

Start date: 2021-11-17
Primary completion: 2022-11-15
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.